Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.54)
# 1,097
Out of 4,876 analysts
15
Total ratings
53.33%
Success rate
7.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Reiterates: Buy | $92 → $116 | $93.82 | +23.64% | 2 | Jun 18, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.57 | +152.10% | 2 | Jun 18, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Buy | $31 | $11.15 | +178.03% | 1 | Jun 17, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $4.05 | +171.60% | 2 | May 19, 2025 | |
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $6.05 | +230.58% | 3 | Mar 18, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.34 | +1,974.07% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.97 | +255.33% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $6.91 | +319.68% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.32 | +657.58% | 1 | Dec 5, 2024 |
Verona Pharma
Jun 18, 2025
Reiterates: Buy
Price Target: $92 → $116
Current: $93.82
Upside: +23.64%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.57
Upside: +152.10%
Capricor Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $31
Current: $11.15
Upside: +178.03%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.05
Upside: +171.60%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $6.05
Upside: +230.58%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.34
Upside: +1,974.07%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.97
Upside: +255.33%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $6.91
Upside: +319.68%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.32
Upside: +657.58%